

Review Form 1.6

Journal Name:	Journal of Pharmaceutical Research International
Manuscript Number:	Ms_JPRI_83922
Title of the Manuscript:	PREVALENCE OF EARLY SUBACUTE STENT THROMBOSIS AFTER PRIMARY PCI IN STEMI PATIENTS
Type of the Article	ORIGINAL STUDY

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<https://www.journalpri.com/index.php/JPRI/editorial-policy>)

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments		
Minor REVISION comments	<p>I consider that the idea of this study, to evaluate the prevalence of early subacute stent thrombosis after primary PCI in STEMI patients is very interesting, considering that acute myocardial infarction is a challenging pathology. The article is well-written and comprehensive. The results are clearly and transparently presented and the set goals correspond to the conclusions. Even though this study included a relatively small number of patients from a single center, I consider that the findings are interesting and that the results obtained can make significant contributions to further large studies.</p> <p>I consider that the article may be accepted for publication after some minor revisions.</p> <ol style="list-style-type: none">1. I recommend defining the antiaggregant used and also if patients needed anticoagulants.2. Which is the period when these patients were selected and included in the study?3. Also, I suggest addressing the future scope and topics that are important and that could not be covered in the manuscript.	<ol style="list-style-type: none">1. The standard anticoagulant and antiplatelet medications given to the patients have been mentioned in the methodology section.2. The period of study was six months in year 2021 as already mentioned in the manuscript.3. The future scopes are discussed in the study limitation section.
Optional/General comments		

PART 2:

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	(If yes, Kindly please write down the ethical issues here in details)	